Observational studyBladder cancer

Association Between Smoking and Risk of Bladder Cancer Among Men and Women

JAMA · 2011281,394 men and 186,134 women
Freedman ND. JAMA. 2011. 306:737
Study type
Observational study
Study name
NIH-AARP
Design
Prospective cohort study (NIH-AARP Diet and Health Study) with a systematic review of earlier prospective cohort studies
Sample size
281,394 men and 186,134 women
Source
JAMA · 2011

In plain words

In this large study, more than four hundred thousand men and women were followed for several years to look at the link between smoking and bladder cancer. The risk of bladder cancer was about four times higher in current smokers, and more than twice as high in former smokers, compared with people who had never smoked. About half of all bladder cancers, in both men and women, were attributed to smoking. The results show that quitting smoking, and never starting, matter for preventing bladder cancer.

Key results

Men: 3896 cases (144.0 per 100,000 person-years); women: 627 cases (34.5 per 100,000 person-years)
Incident bladder cancer cases (over 4,518,941 person-years of follow-up)
HR 2.22 (95% CI: 2.03 to 2.44); NNH 1250
Former smokers vs never smokers
Incidence 119.8 vs 39.8 per 100,000 person-years
HR 4.06 (95% CI: 3.66 to 4.50); NNH 727
Current smokers vs never smokers
Incidence 177.3 vs 39.8 per 100,000 person-years
2.94 (95% CI: 2.45 to 3.54)
Summary risk estimate for current smokers in 7 earlier studies (initiated between 1963 and 1987)
I² 0.0%
Men: 0.50 (95% CI: 0.45 to 0.54); women: 0.52 (95% CI: 0.45 to 0.59)
Population attributable risk (PAR) for ever smoking

Treatment arms and regimens

1Never smokers

Reference group; incidence 39.8 per 100,000 person-years. This is an observational study with no drug intervention.

2Former smokers

Incidence 119.8 per 100,000 person-years. This is an observational study with no drug intervention.

3Current smokers

Incidence 177.3 per 100,000 person-years. This is an observational study with no drug intervention.

Source of the regimen details: Abstract of the paper

Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.

Study population

Men (281,394) and women (186,134) in the NIH-AARP Diet and Health Study cohort who completed a lifestyle questionnaire and were followed from 25 October 1995 to 31 December 2006. Earlier prospective cohort studies of smoking and bladder cancer incidence were also identified through a systematic review.

Endpoints

Main outcome measures: hazard ratio (HR), population attributable risk (PAR) and number needed to harm (NNH).

Safety and side effects

This is an observational study with no therapeutic intervention, so treatment adverse events were not reported.

Clinical significance and place in guidelines

This study shows that in a more recent cohort the relative risk of bladder cancer associated with smoking is higher than estimates from older cohorts, and that the contribution of smoking to this cancer in women is comparable to that in men. These findings underline the importance of smoking prevention and cessation. The abstract does not mention a direct change to clinical guidelines, and the status of recommendations in current guidelines should be checked separately.

Limitations

Based on the abstract, this is an observational study and smoking data came from a lifestyle questionnaire. Other limitations should be checked in the full text of the paper.

This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.